# SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Source: https://onco.cc/trials/nct05351788/  
OnCo record `nct05351788` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sacituzumab tirumotecan, KL-A167, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. is a phase 2 interventional study registered as NCT05351788 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 110 participants planned, started 2022-05-20 and due to reach its primary completion in 2026-08. Interventions recorded: SKB264, KL-A167, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05351788
- Phase: 2
- Setting: A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT05351788: https://clinicaltrials.gov/study/NCT05351788

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [KL-A167](https://onco.cc/drugs/kl-a167/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05351788.json